Diagnosis and treatment of neurofibromatosis type 1 and related orthopedic diseases

References:

[1] Liu D,Yu LY,Wu X,et al.Internalizing and externalizing symptoms in individuals with neurofibromatosis type 1:a systematic review and meta-analysis[J].Syst Rev,2025,14(1):20.DOI:10.1186/s13643-024-02749-0.
[2] Lee TSJ,Chopra M,Kim RH,et al.Incidence and prevalence of neurofibromatosis type 1 and 2:a systematic review and meta-analysis[J].Orphanet J Rare Dis,2023,18(1):292.DOI:10.1186/s13023-023-02911-2.
[3] Mladenov KV,Stücker R.Recent developments in surgical treatment of spinal deformity in pediatric patients:experience from a single-center series of 42 neurofibromatosis type 1 patients[J].Cancers (Basel),2024,16(23):4079.DOI:10.3390/cancers16234079.
[4] Ambade R,Malik S.Tibial dysplasia in neurofibromatosis-1:a rare case report and review of literature[J].J Orthop Case Rep,2024,14(2):7-11.DOI:10.13107/jocr.2024.v14.i02.4198.
[5] Kaspiris A,Vasiliadis E,Iliopoulos ID,et al.Bone mineral density,vitamin D and osseous metabolism indices in neurofibromatosis type 1:a systematic review and meta-analysis[J].Bone,2024,180:116992.DOI:10.1016/j.bone.2023.116992.
[6] Legius E,Messiaen L,Wolkenstein P,et al.Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome:an international consensus recommendation[J].Genet Med,2021,23(8):1506-1513.DOI:10.1038/s41436-021-01170-5.
[7] 中国罕见病联盟Ⅰ型神经纤维瘤病多学科诊疗协作组.Ⅰ型神经纤维瘤病多学科诊治指南(2023版)[J].罕见病研究,2023,2(2):210-230.DOI:10.12376/j.issn.2097-0501.2023.02.009. Multidisciplinary Diagnosis and Treatment Collaboration Group for Neurofibromatosis Type 1 of China Alliance for Rare Diseases.Guidelines for the multidisciplinary diagnosis and treatment of neurofibromatosis type 1(2023 version)[J].J Rare Dis,2023,2(2):210-230.DOI:10.12376/j.issn.2097-0501.2023.02.009.
[8] Ho JD,Ho JAS,Ruddock R,et al.Isolated,nonsyndromic mucocutaneous plexiform neurofibromas:a systematic review of the clinicopathologic features[J].Am J Dermatopathol,2022,44(12):904-912.DOI:10.1097/DAD.0000000000002322.
[9] Ota M,Nobeyama Y,Asahina A.Real-world settings for the surgical treatment of neurofibroma in patients with neurofibromatosis type 1[J].JMA J,2024,7(2):205-212.DOI:10.31662/jmaj.2023-0161.
[10] Ndiaye L,Ndiaye A?,Foba ML,et al.Management of cervico-cephalic plexiform neurofibromas:about 35 cases[J].Ann Chir Plast Esthet,2020,65(4):306-312.DOI:10.1016/j.anplas.2020.03.002.
[11] Nelson CN,Dombi E,Rosenblum JS,et al.Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1[J].J Neurosurg,2020,133(5):1516-1526.DOI:10.3171/2019.7.JNS191353.
[12] Friedrich RE,Modemann M.Neurofibromatosis type 1-associated plexiform neurofibromas of the face and adjacent head regions:topography of lesions and surgical treatment data of 179 patients[J].J Maxillofac Oral Surg,2023,22(3):511-524.DOI:10.1007/s12663-022-01838-8.
[13] Han YH,Li BY,Yu XK,et al.Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas:a systematic review and meta-analysis[J].J Neurol,2024,271(5):2379-2389.DOI:10.1007/s00415-024-12301-8.
[14] Weiss B,Widemann BC,Wolters P,et al.Sirolimus for non-progressive NF1-associated plexiform neurofibromas:an NF clinical trials consortium phase Ⅱ study[J].Pediatr Blood Cancer,2014,61(6):982-986.DOI:10.1002/pbc.24873.
[15] Zheng Y,Zhu GH,Liu YX,et al.Case series of congenital pseudarthrosis of the tibia unfulfilling neurofibromatosis type 1 diagnosis:21% with somatic NF1 haploinsufficiency in the periosteum[J].Hum Genet,2022,141(8):1371-1383.DOI:10.1007/s00439-021-02429-2.
[16] 杨戈,冯馨慧,赵卫华,等.单中心497例先天性胫骨假关节患儿的临床特征分析[J].中华外科杂志,2024,62(9):864-869.DOI:10.3760/cma.j.cn112139-20240328-00150. Yang G,Feng XH,Zhao WH,et al.The clinical characteristics of 497 children with congenital pseudarthrosis of the tibia[J].Chin J Surg,2024,62(9):864-869.DOI:10.3760/cma.j.cn112139-20240328-00150.
[17] Todderud JE,Carlson SW,Larson AN.Guided growth to treat anterolateral tibial bowing associated with congenital pseudarthrosis of the tibia[J].J Pediatr Orthop,2024,44(6):e560-e565.DOI:10.1097/BPO.0000000000002683.
[18] Siebert MJ,Makarewich CA.Anterolateral tibial bowing and congenital pseudoarthrosis of the tibia:current concept review and future directions[J].Curr Rev Musculoskelet Med,2022,15(6):438-446.DOI:10.1007/s12178-022-09779-y.
[19] Perrin S,Protic S,Bretegnier V,et al.MEK-SHP2 inhibition prevents tibial pseudarthrosis caused by NF1 loss in Schwann cells and skeletal stem/progenitor cells[J].Sci Transl Med,2024,16(753):eadj1597.DOI:10.1126/scitranslmed.adj1597.
[20] 刘尧喜,谭谦,刘昆,等.新型可延伸髓内棒治疗儿童先天性胫骨假关节的临床研究[J].临床小儿外科杂志,2022,21(10):953-957.DOI:10.3760/cma.j.cn101785-202105042-010. Liu YX,Tan Q,Liu K,et al.Application of "telescopic rod" in combined surgical technique for the treatment of congenital pseudarthrosis of the tibia in children[J].DOI:10.3760/cma.j.cn101785-202105042-010.
[21] Rastogi A,Agarwal A.Surgical treatment options for congenital pseudarthrosis of tibia in children:cross-union versus other options:a systematic review[J].J Pediatr Orthop B,2022,31(2):139-149.DOI:10.1097/BPB.0000000000000924.
[22] 中华医学会小儿外科学分会小儿骨科学组.先天性胫骨假关节临床诊治专家共识(2024版)[J].临床小儿外科杂志,2024,23(12):1106-1116.DOI:10.3760/cma.j.cn101785-202412029-002. Pediatric Orthopedics Group,Chinese Society of Pediatric Surgery.Expert consensus on the clinical diagnosis and treatment of congenital pseudarthrosis of the tibia (2024 edition)[J].J Clin Ped Sur,2024,23(12):1106-1116.DOI:10.3760/cma.j.cn101785-202412029-002.
[23] Zayda AI,Mesregah MK,Zalalo SH,et al.Functional and radiological outcomes after treatment of congenital pseudarthrosis of the tibia using the Ilizarov technique:a retrospective single-center study[J].J Orthop Traumatol,2022,23(1):48.DOI:10.1186/s10195-022-00667-2.
[24] Paley D.Congenital pseudarthrosis of the tibia:biological and biomechanical considerations to achieve union and prevent refracture[J].J Child Orthop,2019,13(2):120-133.DOI:10.1302/1863-2548.13.180147.
[25] Nǎstase F,Radaschin DS,Nicule? E,et al.Orthopaedic manifestations of neurofibromatosis type 1:a case report[J].Exp Ther Med,2022,23(2):135.DOI:10.3892/etm.2021.11058.
[26] Mladenov KV,Spiro AS,Krajewski KL,et al.Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1(NF-1)[J].Childs Nerv Syst,2020,36(10):2409-2425.DOI:10.1007/s00381-020-04775-4.
[27] Kaspiris A,Savvidou OD,Vasiliadis ES,et al.Current aspects on the pathophysiology of bone metabolic defects during progression of scoliosis in neurofibromatosis type 1[J].J Clin Med,2022,11(2):444.DOI:10.3390/jcm11020444.
[28] Jalilova A,Cocca A.Efficacy of bisphosphonate in patients with neurofibromatosis type 1[J].J Bone Metab,2025,32(1):1-10.DOI:10.11005/jbm.24.809.
[29] Gross AM,Plotkin SR,Watts NB,et al.Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1[J].Clin Trials,2024,21(1):29-39.DOI:10.1177/17407745231201338.
[30] Lalvani S,Brown RM.Neurofibromatosis type 1:optimizing management with a multidisciplinary approach[J].J Multidiscip Healthc,2024,17:1803-1817.DOI:10.2147/JMDH.S362791.